These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33948826)

  • 21. Characterization of POLE c.1373A > T p.(Tyr458Phe), causing high cancer risk.
    Rocque MJ; Leipart V; Kumar Singh A; Mur P; Olsen MF; Engebretsen LF; Martin-Ramos E; Aligué R; Sætrom P; Valle L; Drabløs F; Otterlei M; Sjursen W
    Mol Genet Genomics; 2023 May; 298(3):555-566. PubMed ID: 36856825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes.
    Magrin L; Fanale D; Brando C; Fiorino A; Corsini LR; Sciacchitano R; Filorizzo C; Dimino A; Russo A; Bazan V
    Oncogene; 2021 Oct; 40(40):5893-5901. PubMed ID: 34363023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated POLE variants.
    Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
    Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas.
    Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J
    Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures.
    Castellsagué E; Li R; Aligue R; González S; Sanz J; Martin E; Velasco À; Capellá G; Stewart CJR; Vidal A; Majewski J; Rivera B; Polak P; Matias-Guiu X; Brunet J; Foulkes WD
    Hum Mutat; 2019 Jan; 40(1):36-41. PubMed ID: 30362666
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing.
    Chubb D; Broderick P; Frampton M; Kinnersley B; Sherborne A; Penegar S; Lloyd A; Ma YP; Dobbins SE; Houlston RS
    J Clin Oncol; 2015 Feb; 33(5):426-32. PubMed ID: 25559809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rare germline variants in POLE and POLD1 encoding the catalytic subunits of DNA polymerases ε and δ in glioma families.
    Weber CAM; Krönke N; Volk V; Auber B; Förster A; Trost D; Geffers R; Esmaeilzadeh M; Lalk M; Nabavi A; Samii A; Krauss JK; Feuerhake F; Hartmann C; Wiese B; Brand F; Weber RG
    Acta Neuropathol Commun; 2023 Nov; 11(1):184. PubMed ID: 37990341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
    Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
    Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population.
    Yao J; Gong Y; Zhao W; Han Z; Guo S; Liu H; Peng X; Xiao W; Li Y; Dang S; Liu G; Li L; Huang T; Chen S; Song L
    Sci Rep; 2019 Oct; 9(1):15767. PubMed ID: 31673068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase δ mutation in human cells.
    Mertz TM; Baranovskiy AG; Wang J; Tahirov TH; Shcherbakova PV
    Oncogene; 2017 Aug; 36(31):4427-4433. PubMed ID: 28368425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring Co-occurring POLE Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
    Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
    Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. POLE/POLD1 mutation and tumor immunotherapy.
    Ma X; Dong L; Liu X; Ou K; Yang L
    J Exp Clin Cancer Res; 2022 Jul; 41(1):216. PubMed ID: 35780178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interpretation of somatic POLE mutations in endometrial carcinoma.
    León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
    J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Race, Prevalence of POLE and POLD1 Alterations, and Survival Among Patients With Endometrial Cancer.
    Zheng S; Donnelly ED; Strauss JB
    JAMA Netw Open; 2024 Jan; 7(1):e2351906. PubMed ID: 38231514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Di-genic inheritance of germline POLE and PMS2 pathogenic variants causes a unique condition associated with pediatric cancer predisposition.
    Michaeli O; Ladany H; Erez A; Ben Shachar S; Izraeli S; Lidzbarsky G; Basel-Salmon L; Biskup S; Maruvka YE; Toledano H; Goldberg Y
    Clin Genet; 2022 Apr; 101(4):442-447. PubMed ID: 34967012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenotype of POLE-mutated endometrial cancer.
    Imboden S; Nastic D; Ghaderi M; Rydberg F; Rau TT; Mueller MD; Epstein E; Carlson JW
    PLoS One; 2019; 14(3):e0214318. PubMed ID: 30917185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of an MSI-positive colon tumor with aberrant DNA methylation in a PPAP patient.
    Yamaguchi K; Shimizu E; Yamaguchi R; Imoto S; Komura M; Hatakeyama S; Noguchi R; Takane K; Ikenoue T; Gohda Y; Yano H; Miyano S; Furukawa Y
    J Hum Genet; 2019 Aug; 64(8):729-740. PubMed ID: 31089268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
    Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
    J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
    Ostroverkhova D; Tyryshkin K; Beach AK; Moore EA; Masoudi-Sobhanzadeh Y; Barbari SR; Rogozin IB; Shaitan KV; Panchenko AR; Shcherbakova PV
    Cell Rep; 2024 Jan; 43(1):113655. PubMed ID: 38219146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity.
    Ma X; Riaz N; Samstein RM; Lee M; Makarov V; Valero C; Chowell D; Kuo F; Hoen D; Fitzgerald CWR; Jiang H; Alektiar J; Alban TJ; Juric I; Parthasarathy PB; Zhao Y; Sabio EY; Verma R; Srivastava RM; Vuong L; Yang W; Zhang X; Wang J; Chu LK; Wang SL; Kelly DW; Pei X; Chen J; Yaeger R; Zamarin D; Zehir A; Gönen M; Morris LGT; Chan TA
    Nat Genet; 2022 Jul; 54(7):996-1012. PubMed ID: 35817971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.